Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | PRKACA | P17612 | 1/20 | 0.47 |
| ▸ | PRKACG | P22612 | 1/20 | 0.47 |
| ▸ | PRKACB | P22694 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 11/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213851 | 0.91 | L3MBTL1 (0.46) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL213970 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL216364 | 0.85 | NTRK1 (0.49) | SMN1; SMN2MEN1KMT2APRKACAROCK1 | |
| SCHEMBL215699 | 0.84 | MAPT (0.43) | SMN1; SMN2KMT2AKDM4EPOLB | |
| SCHEMBL216143 | 0.83 | NPC1 (0.49) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL213393 | 0.81 | MAPT (0.46) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL216561 | 0.81 | MAPT (0.49) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL216093 | 0.80 | MAPT (0.49) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL214763 | 0.80 | NTRK1 (0.49) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL214139 | 0.80 | MAPT (0.49) | SMN1; SMN2MEN1KMT2AKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-8088767-B2 | JAK-2 modulators and methods of use | EXELIXIS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | SMN1; SMN2 2516/4885MEN1 3504/4885KMT2A 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.